NASH Alliance
  • Home
  • About
    • What is NASH?
    • About NASH Alliance
  • Resources
    • NASH Prevention
    • News
    • Publications
    • Additional Information
  • Events
  • Contact
Select Page
Simultaneous MR quantification of hepatic fat content

Simultaneous MR quantification of hepatic fat content

by ltsiwpadmin | Jul 5, 2017 | Overview & Epidemiology, Publications

Abstract Non-alcoholic steatohepatitis (NASH) is characterized at histology by steatosis, hepatocyte ballooning and inflammatory infiltrates, with or without fibrosis. Although diamagnetic material in fibrosis and inflammation can be detected with quantitative...
New treatments in non-alcoholic fatty liver disease

New treatments in non-alcoholic fatty liver disease

by ltsiwpadmin | Jul 4, 2017 | Diagnostics & Therapeutic Advancements, Publications

Abstract BACKGROUND Non-alcoholic fatty liver disease is the fastest growing cause of liver disease in the Western world, yet there is no approved pharmacotherapy. While lifestyle modifications remain the mainstay of treatment, only a proportion of individuals are...
Simultaneous MR quantification of hepatic fat content

Protein profiling and functional analysis of liver mitochondria

by ltsiwpadmin | Jun 30, 2017 | Overview & Epidemiology, Publications

Abstract Mitochondrial dysfunction is closely associated with the pathogenesis of nonalcoholic steatohepatitis (NASH). The aim of the present study was to comprehensively determine mitochondrial abnormalities in NASH by detecting the proteomics in liver mitochondria...
Liver Biopsy in Type 2 Diabetes: Implications for NASH

Liver Biopsy in Type 2 Diabetes: Implications for NASH

by ltsiwpadmin | Jun 1, 2017 | Policy & Public Affairs, Publications

Abstract Recent studies report a prevalence of non-alcoholic fatty liver disease (NAFLD) of between 70% and 80% in patients with metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM). Nevertheless, it is not possible to differentiate between simple steatosis and...
Liver Biopsy in Type 2 Diabetes: Implications for NASH

Liver Safety of Statins in Prediabetes or T2DM and NASH

by ltsiwpadmin | Jun 1, 2017 | Policy & Public Affairs, Publications

Abstract CONTEXT Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity. OBJECTIVE To prospectively assess the long-term safety of statins in patients with prediabetes/type 2...
Liver Biopsy in Type 2 Diabetes: Implications for NASH

Liver and Cardiovascular Damage in Patients with NASH

by ltsiwpadmin | May 26, 2017 | Policy & Public Affairs, Publications

Abstract BACKGROUND & AIMS Lean nonalcoholic fatty liver disease (NAFLD) is defined as NAFLD that develops in patients with a body mass index (BMI) less than 25 kg/m2. We investigated the differences between lean NAFLD and NAFLD in overweight and obese persons,...
« Older Entries
Next Entries »

Recent Posts

  • Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry
  • About Danielle P. Turnipseed, J.D., M.H.S.A., M.P.P.
  • About Billy Wynne, J.D.
  • About Barret Thornhill, J.D.
  • Fatty liver disease strikes Latino children like a ‘silent tsunami’

Recent Comments

    Archives

    • October 2019
    • September 2019
    • July 2019
    • June 2019
    • April 2019
    • December 2018
    • October 2018
    • July 2017
    • June 2017
    • May 2017

    Categories

    • Diagnostics & Therapeutic Advancements
    • News
    • Overview & Epidemiology
    • Policy & Public Affairs
    • Prevention & Management
    • Publications
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    NASH Alliance

    [email protected]

    Follow us on twitter